PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Summary

This research study is evaluating the experimental drug palbociclib in combination with another experimental drug PD-0325901 as a possible treatment for cancers with KRAS mutations, particularly for those which started in the lung.

Timeline

Start

2014-01

Primary completion

2017-11-01

Completion

2021-06-30

Drugs

Indications